What is Noze?
Noze operates at the intersection of biotechnology and digital sensing, pioneering the development of the world's first digital nose. By leveraging sophisticated sensors to analyze volatile organic compounds emitted through breath and skin, the company aims to transform the landscape of medical diagnostics. Its flagship platform, DiagNoze, is engineered to provide real-time health assessments, offering a non-invasive alternative to traditional testing methods. By targeting critical sectors including healthcare, safety, and food integrity, Noze is establishing a new paradigm for point-of-care diagnostics, effectively digitizing the human olfactory experience to improve global health outcomes.
How much funding has Noze raised?
Noze has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2024): $5M with participation from Bill & Melinda Gates Foundation
Key Investors in Noze
Bill & Melinda Gates Foundation
A philanthropic organization dedicated to enhancing healthcare access and reducing global health disparities through strategic investments in innovative medical technologies.
What's next for Noze?
Following this major enterprise-level funding, Noze is expected to prioritize the clinical validation and scaling of its DiagNoze platform. The strategic allocation of capital will likely focus on refining sensor sensitivity and expanding the diagnostic library of detectable health markers. As the company transitions from development to broader market integration, the focus will shift toward establishing partnerships with healthcare providers and safety organizations. This growth phase is critical for proving the efficacy of breath-based diagnostics in real-world environments, ultimately aiming to integrate these sensing capabilities into everyday health monitoring ecosystems.
See full Noze company page
